Sajeev Menon, MD
Endocrinology, Diabetes & Metabolism · Overland Park, KSNPI 1811988819
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $20,175 of the $24,739 with a category attached, or 81.6%. AstraZeneca accounts for 61.0% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2019 at $16,474 and has fallen 97.7% since, to $387 in 2025. Among endocrinology, diabetes & metabolism clinicians in KS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 290 payments — averaging $85.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$15K
- Valeritas, Inc.$4K
- Corcept Therapeutics$2K
- Novo Nordisk$682
- Chiesi USA, Inc.$325
- Mannkind Corporation$313
- plus $2K from 22 others
Across 4 payments — averaging $362.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$1K
What the payments were for
- Speaking & faculty fees$20,17582%
- Travel & lodging$2851%
- Food & beverage$4,15117%
- Education$80%
- Gifts$1190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 27 | $15,090 |
| Valeritas, Inc. | 28 | $4,337 |
| Corcept Therapeutics | 38 | $1,983 |
| Novo Nordisk | 78 | $682 |
| Chiesi USA, Inc. | 1 | $325 |
| Mannkind Corporation | 10 | $313 |
| Lilly USA, LLC | 13 | $294 |
| Xeris Pharmaceuticals, Inc. | 39 | $277 |
| Amgen | 5 | $241 |
| Medtronic(2 entities) | 8 | $176 |
| Insulet Corporation | 8 | $168 |
| Radius Health, Inc. | 2 | $148 |
| Pfizer | 7 | $125 |
| GSK | 2 | $112 |
| Abbott | 1 | $91 |
| Tandem Diabetes Care, Inc. | 3 | $66 |
| AbbVie | 4 | $62 |
| Dexcom, Inc. | 3 | $43 |
| Ascensia Diabetes Care US Inc. | 2 | $35 |
| Boehringer Ingelheim | 2 | $33 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Cequr Corporation | 1 | $26 |
| BD | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $17 |
| Eisai Inc. | 1 | $15 |
| Antares Pharma, Inc. | 1 | $13 |
| Endo Pharmaceuticals Inc. | 1 | $12 |
| Clarus Therapeutics Inc. | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,739 in reported general payments places this provider in the 90th percentile of 50 endocrinology, diabetes & metabolism providers in Kansas.
See all endocrinology, diabetes & metabolism providers in Kansas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 122 | $137,968 |
| MounjaroTirzepatide | 69 | $93,411 |
| JardianceEmpagliflozin | 66 | $66,326 |
| Tresiba Flextouch U-200Insulin Degludec | 45 | $43,291 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 14 | $28,384 |
| Tresiba Flextouch U-100Insulin Degludec | 40 | $27,391 |
| Novolog FlexpenInsulin Aspart | 76 | $21,654 |
| FiaspInsulin Aspart (Niacinamide) | 20 | $20,352 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 22 | $19,305 |
| Humalog Kwikpen U-100Insulin Lispro | 43 | $17,572 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 92 | $16,652 |
| V-Go 40Sub-Q Insulin Device, 40 Unit | 25 | $15,662 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 26 | $12,963 |
| FarxigaDapagliflozin Propanediol | 29 | $10,251 |
| NovologInsulin Aspart | 35 | $8,647 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Novolog | $682 | $166,967177 claims |
| Lilly USA, LLCMounjaro, Humalog, Insulin Lispro | $294 | $101,300122 claims |
| Boehringer IngelheimJardiance | $33 | $66,32666 claims |
| AstraZenecaFarxiga | $15,090 | $10,25129 claims |
| AbbVieSynthroid | $62 | $5,81773 claims |
| Sanofi-aventis U.S. LLCLantus | $31 | $1,98017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 50 endocrinology, diabetes & metabolism providers in Kansas.
Other endocrinology, diabetes & metabolism in Overland Park
- Michael SokolOverland Park$227K
- M Yaser MounlaOverland Park$9K
- Mini AbrahamOverland Park$550
- Marie GriffinOverland Park$303
- Jeffrey KallsenOverland Park$80
- Dany ZayourWichita$744K
- Andrew GreenShawnee Mission$322K
- Rami MortadaWichita$105K
- Georges ElhomsyWichita$14K
- Richard GomendozaSalina$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.